Neurotherapeutics

, Volume 4, Issue 4, pp 666–675

Modulating co-stimulation

Review Article

Summary

The modulation of co-stimulatory pathways represents a novel therapeutic strategy to regulate autoimmune diseases. Auto-reactive CD4+ T cells play a critical role in initiating the immune response leading to inflammation and autoimmune diseases. Blocking co-stimulatory signals prevents T-cell activation, thus diminishing autoimmune responses and possibly preventing the progression of autoimmune disease. Blockade of several co-stimulatory pathways has been investigated in animal models and has led to clinical trials testing specific blocking agents in humans. In this review we will describe the role of co-stimulatory pathways, primarily the CD28-B7 pathway, in autoimmune diseases, and we will present in vivo and in vitro studies supporting the efficacy of co-stimulation blockade in animal models of autoimmune disease. Finally, we will discuss the clinical therapeutic efficacy of blocking monoclonal antibodies in preventing or reducing auto-antigen driven T-cell activation in humans with particular attention to the CD28/B7 pathway. Inhibiting co-stimulatory molecule interactions by using monoclonal antibodies seems to be an original approach to regulate autoimmune diseases in humans.

Key Words

T-cell activation CD28/B7 molecules co-stimulation blockade CT1A-4 Ig EAE/MS monoclonal antibody (mAb) 

References

  1. 1.
    Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607–609.PubMedGoogle Scholar
  2. 2.
    DeSilva DR, Urdahl KB, Jenkins MK. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J Immunol 1991;147:3261–3267.PubMedGoogle Scholar
  3. 3.
    Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147:2461–2466.PubMedGoogle Scholar
  4. 4.
    Ramsdell F, Jenkins M, Dinh Q, Fowlkes BJ. The majority of CD4+8-thymocytes are functionally immature. J Immunol 1991; 147:1779–1785.PubMedGoogle Scholar
  5. 5.
    Norton SD, Hovinen DE, Jenkins MK. IL-2 secretion and T cell clonal anergy are induced by distinct biochemical pathways. J Immunol 1991;146:1125–1129.PubMedGoogle Scholar
  6. 6.
    Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996;273:104–106.PubMedGoogle Scholar
  7. 7.
    Sloan-Lancaster J, Evavold BD, Allen PM. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 1993;363:156–159.PubMedGoogle Scholar
  8. 8.
    Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23: 515–548.PubMedGoogle Scholar
  9. 9.
    Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23–68.PubMedGoogle Scholar
  10. 10.
    Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996;157:1333–1336.PubMedGoogle Scholar
  11. 11.
    Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533–2540.PubMedGoogle Scholar
  12. 12.
    Cross AH, Girard TJ, Giacoletto KS, et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest 1995;95:2783–2789.PubMedGoogle Scholar
  13. 13.
    Miller SD, Vanderlugt CL, Lenschow DJ, et al. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995;3:739–745.PubMedGoogle Scholar
  14. 14.
    Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707–718.PubMedGoogle Scholar
  15. 15.
    Racke MK, Scott DE, Quigley L, et al. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995;96:2195–2203.PubMedGoogle Scholar
  16. 16.
    Chang TT, Jabs C, Sobel RA, Kuchroo VK, Sharpe AH. Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med 1999;190:733–740.PubMedGoogle Scholar
  17. 17.
    Issazadeh S, Navikas V, Schaub M, Sayegh M, Khoury S. Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. J Immunol 1998;161: 1104–1112.PubMedGoogle Scholar
  18. 18.
    Gallon L, Chandraker A, Issazadeh S, et al. Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J Immunol 1997;159:4212–4216.PubMedGoogle Scholar
  19. 19.
    Williams K, Ulvestad E, Antel JP. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur J Immunol 1994;24:3031–3037.PubMedGoogle Scholar
  20. 20.
    Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995; 182:1985–1996.PubMedGoogle Scholar
  21. 21.
    Genc K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997;99:2664–2671.PubMedGoogle Scholar
  22. 22.
    Peterson KE, Sharp GC, Tang H, Braley-Mullen H. B7.2 has opposing roles during the activation versus effector stages of experimental autoimmune thyroiditis. J Immunol 1999;162:1859–1867.PubMedGoogle Scholar
  23. 23.
    Bachmaier K, Pummerer C, Shahinian A, et al. Induction of autoimmunity in the absence of CD28 costimulation. J Immunol 1996;157:1752–1757.PubMedGoogle Scholar
  24. 24.
    Tada Y, Nagasawa K, Ho A, et al. CD28-deficient mice are highly resistant to collagen-induced arthritis. J Immunol 1999; 162:203–208.PubMedGoogle Scholar
  25. 25.
    Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-l and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181:1145–1155.PubMedGoogle Scholar
  26. 26.
    Perrin PJ, Scott D, Quigley L, et al. Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol 1995;154:1481–1490.PubMedGoogle Scholar
  27. 27.
    Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265: 1225–1227.PubMedGoogle Scholar
  28. 28.
    Oliveira-dos-Santos AJ, Ho A, Tada Y, et al. CD28 costimulation is crucial for the development of spontaneous autoimmune encephalomyelitis. J Immunol 1999;162:4490–4495.PubMedGoogle Scholar
  29. 29.
    Girvin AM, Dal Canto MC, Rhee L, et al. A critical role for B7/CD28 costimulation in experimental autoimmune encephalomyelitis: a comparative study using costimulatory molecule-deficient mice and monoclonal antibody blockade. J Immunol 2000; 164:136–143.PubMedGoogle Scholar
  30. 30.
    Ben-Nun A, Wekerle H, Cohen IR. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981;11:195.PubMedGoogle Scholar
  31. 31.
    Vandenbark AA, Gill T, Offner H. A myelin basic protein-specific T lymphocyte line that mediates experimental autoimmune encephalomyelitis. J Immunol 1985;153:223.Google Scholar
  32. 32.
    Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990;8:579–621.PubMedGoogle Scholar
  33. 33.
    Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Amason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46: 12–18.PubMedGoogle Scholar
  34. 34.
    Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183–187.PubMedGoogle Scholar
  35. 35.
    Fritz RB, McFarlin DE. Encephalitogenic epitopes of myelin basic protein. Chem Immunol 1989;46: 101–125.PubMedGoogle Scholar
  36. 36.
    Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992;10:153–187.PubMedGoogle Scholar
  37. 37.
    Karandikar NJ, Vanderlugt CL, Eagar T, Tan L, Bluestone JA, Miller SD. Tissue-specific up-regulation of B7-1 expression and function during the course of murine relapsing experimental autoimmune encephalomyelitis. J Immunol 1998; 161:192–199.PubMedGoogle Scholar
  38. 38.
    Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA. CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996;184:783–788.PubMedGoogle Scholar
  39. 39.
    Hurwitz AA, Sullivan TJ, Krummel MF, Sobel RA, Allison JP. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. J Neuroimmunol 1997;73:57–62.PubMedGoogle Scholar
  40. 40.
    Croxford JL, O’Neill JK, Ali RR, et al. Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis. Eur J Immunol 1998;28:3904–3916.PubMedGoogle Scholar
  41. 41.
    Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999;163:1704–1710.PubMedGoogle Scholar
  42. 42.
    Schaub M, Issazadeh S, Stadibauer TH, Peach R, Sayegh MH, Khoury SJ. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 1999;96:158–166.PubMedGoogle Scholar
  43. 43.
    Noelle RJ, Ledbetter JA, Aruffo A. CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. Immunol Today 1992;13:431–433.PubMedGoogle Scholar
  44. 44.
    Marshall LS, Aruffo A, Ledbetter JA, Noelle RJ. The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39. J Clin Immunol 1993;13:165–174.PubMedGoogle Scholar
  45. 45.
    Klaus GG, Choi MS, Holman M. Properties of mouse CD40. Ligation of CD40 activates B cells via a Ca(++)-dependent, FK506-sensitive pathway. Eur J Immunol 1994;24:3229–3232.PubMedGoogle Scholar
  46. 46.
    Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180:1263–1272.PubMedGoogle Scholar
  47. 47.
    Khoury SJ, Akalin E, Chandraker A, et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995; 155:4521–4524.PubMedGoogle Scholar
  48. 48.
    Schaub M, Stadibauer TH, Sayegh MH. CTLA4Ig: effects on cellular and humoral immunity and macrophage activation. Exp Nephrol 1997;5:370–374.PubMedGoogle Scholar
  49. 49.
    Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993;261:1328–1330.PubMedGoogle Scholar
  50. 50.
    Early GS, Zhao W, Bums CM. Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black × New Zealand white mice. Response correlates with the absence of an anti-antibody response. J Immunol 1996;157:3159–3164.PubMedGoogle Scholar
  51. 51.
    Daikh DI, Finck BK, Linsley PS, Hollenbaugh D, Wofsy D. Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159:3104–3108.PubMedGoogle Scholar
  52. 52.
    Herold KC, Lu J, Rulifson I, et al. Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J Immunol 1997;159:4150–4153.PubMedGoogle Scholar
  53. 53.
    Sayegh MH, Turka LA. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 1995;6:1143–1150.PubMedGoogle Scholar
  54. 54.
    Khoury S, Sayegh MH, Turka LA. Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease. Int Rev Immunol 1999;18:185–199.PubMedGoogle Scholar
  55. 55.
    Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;l:405–413.Google Scholar
  56. 56.
    Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248–255.PubMedGoogle Scholar
  57. 57.
    Van Seventer GA, Shimizu Y, Horgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990;144:4579–4586.PubMedGoogle Scholar
  58. 58.
    Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989;341:619–624.PubMedGoogle Scholar
  59. 59.
    Staunton DE, Dustin ML, Springer TA. Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature 1989;339:61–64.PubMedGoogle Scholar
  60. 60.
    Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol 2000; 115:333.PubMedGoogle Scholar
  61. 61.
    Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000;42:428–435.PubMedGoogle Scholar
  62. 62.
    Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology 2001;121:268–274.PubMedGoogle Scholar
  63. 63.
    von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348:68–72.Google Scholar
  64. 64.
    Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910.PubMedGoogle Scholar
  65. 65.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375–381.PubMedGoogle Scholar
  66. 66.
    Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and Interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353:369–374.PubMedGoogle Scholar
  67. 67.
    Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005;353:362–368.PubMedGoogle Scholar
  68. 68.
    Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8:765–772.PubMedGoogle Scholar
  69. 69.
    Liang SC, Latchman YE, Buhlmann JE, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol 2003;33:2706–2716.PubMedGoogle Scholar
  70. 70.
    Rodig N, Ryan T, Allen JA, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol 2003;33:3117–3126.PubMedGoogle Scholar
  71. 71.
    Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027–1034.PubMedGoogle Scholar
  72. 72.
    Latchman Y, Wood CR, Chemova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261–268.PubMedGoogle Scholar
  73. 73.
    Tseng SY, Otsuji M, Gorski K, et al. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001;193:839–846.PubMedGoogle Scholar
  74. 74.
    Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365–1369.PubMedGoogle Scholar
  75. 75.
    Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141–151.PubMedGoogle Scholar
  76. 76.
    Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198:63–69.PubMedGoogle Scholar
  77. 77.
    Salama AD, Chitnis T, Imitola J, et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med 2003;198:71–78.PubMedGoogle Scholar
  78. 78.
    Hatachi S, Iwai Y, Kawano S, et al. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 2003;30:1410–1419.PubMedGoogle Scholar
  79. 79.
    Chitnis T, Najafian N, Abdallah KA, et al. CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001;107:575–583.PubMedGoogle Scholar
  80. 80.
    Krakauer M, Sorensen PS, Sellebjerg F. CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. J Neuroimmunol 2006;181:157–164.PubMedGoogle Scholar
  81. 81.
    Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350–354.PubMedGoogle Scholar
  82. 82.
    Zhang JY, Zhang Z, Wang X, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007; 109:4671–4678.PubMedGoogle Scholar
  83. 83.
    Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006;203:2223–2227.PubMedGoogle Scholar
  84. 84.
    Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006;12:1198–1202.PubMedGoogle Scholar
  85. 85.
    Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006;203:2281–2292.PubMedGoogle Scholar
  86. 86.
    Lucas PJ, Negishi I, Nakayama K, Fields LE, Loh DY. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J Immunol 1995;154:5757–5768.PubMedGoogle Scholar
  87. 87.
    Walunas TL, Sperling AI, Khattri R, Thompson CB, Bluestone JA. CD28 expression is not essential for positive and negative selection of thymocytes or peripheral T cell tolerance. J Immunol 1996;156:1006–1013.PubMedGoogle Scholar
  88. 88.
    Sperling AI, Auger JA, Ehst BD, Rulifson IC, Thompson CB, Bluestone JA. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J Immunol 1996;157:3909–3917.PubMedGoogle Scholar
  89. 89.
    Bachmann MF, McKall-Faienza K, Schmits R, et al. Distinct roles for LFA-1 and CD28 during activation of naive T cells: adhesion versus costimulation. Immunity 1997;7:549–557.PubMedGoogle Scholar
  90. 90.
    Wells AD, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Invest 1997;100:3173–3183.PubMedGoogle Scholar
  91. 91.
    Gudmundsdottir H, Wells AD, Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferative capacity. J Immunol 1999;162:5212–5223.PubMedGoogle Scholar
  92. 92.
    Fraser JD, Irving BA, Crabtree GR, Weiss A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science 1991;251:313–316.PubMedGoogle Scholar
  93. 93.
    Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J Immunol 1999;162:1947–1951.PubMedGoogle Scholar
  94. 94.
    Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunol 1997;158:5791–5796.PubMedGoogle Scholar
  95. 95.
    Vella AT, Mitchell T, Groth B, et al. CD28 engagement and proinflammatory cytokines contribute to T cell expansion and long-term survival in vivo. J Immunol 1997;158:4714–4720.PubMedGoogle Scholar
  96. 96.
    Kearney ER, Walunas TL, Karr RW, et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J Immunol 1995;155:1032–1036.PubMedGoogle Scholar
  97. 97.
    Delon J, Germain RN. Information transfer at the immunological synapse. Curr Biol 2000;10:R923–933.PubMedGoogle Scholar
  98. 98.
    Croft M, Bradley LM, Swain SL. Naive versus memory CD4 T cell response to antigen. Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol 1994;152:2675–2685.PubMedGoogle Scholar
  99. 99.
    Howland KC, Ausubel LJ, London CA, Abbas AK. The roles of CD28 and CD40 ligand in T cell activation and tolerance. J Immunol 2000;164:4465–4470.PubMedGoogle Scholar
  100. 100.
    London CA, Lodge MP, Abbas AK. Functional responses and costimulator dependence of memory CD4+ T cells. J Immunol 2000;164:265–272.PubMedGoogle Scholar
  101. 101.
    Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest 1998;101:725–730.PubMedGoogle Scholar
  102. 102.
    Teh HS, Teh SJ. High concentrations of antigenic ligand activate and do not tolerize naive CD4 T cells in the absence of CD28/B7 costimulation. Cell Immunol 1997;179:74–83.PubMedGoogle Scholar
  103. 103.
    Scholz C, Patton KT, Anderson DE, Freeman GJ, Hafler DA. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J Immunol 1998;160:1532–1538.PubMedGoogle Scholar
  104. 104.
    Lin H, Boiling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801–1806.PubMedGoogle Scholar
  105. 105.
    Weber CJ, Hagler MK, Chryssochoos JT, et al. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice. Cell Transplant 1997;6:505–508.PubMedGoogle Scholar
  106. 106.
    Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46:1470–1479.PubMedGoogle Scholar
  107. 107.
    Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097–1101.PubMedGoogle Scholar
  108. 108.
    Satoh J, Paty DW, Kim SU. Differential effects of beta and gamma interferons on expression of major histocompatibility complex antigens and intercellular adhesion molecule-1 in cultured fetal human astrocytes. Neurology 1995;45: 367–373.PubMedGoogle Scholar
  109. 109.
    Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000;12:431–440.PubMedGoogle Scholar
  110. 110.
    Tang Q, Henriksen KJ, Boden EK, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003;171:3348–3352.PubMedGoogle Scholar
  111. 111.
    Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003;349:1907–1915.PubMedGoogle Scholar
  112. 112.
    Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263–2271.PubMedGoogle Scholar
  113. 113.
    Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243–1252.PubMedGoogle Scholar
  114. 114.
    Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681–694.PubMedGoogle Scholar
  115. 115.
    Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005;353:770–781.PubMedGoogle Scholar
  116. 116.
    Amason BG. Relevance of experimental allergic encephalomyelitis to multiple sclerosis. Neurol Clin 1983;l: 765–782.Google Scholar
  117. 117.
    Koh DR, Ho A, Rahemtulla A, Penninger J, Mak TW. Experimental allergic encephalomyelitis (EAE) in mice lacking CD4+ T cells. Eur J Immunol 1994;24:2250–2253.PubMedGoogle Scholar
  118. 118.
    Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990;247:718–721.PubMedGoogle Scholar
  119. 119.
    Griggs ND, Agersborg SS, Noelle RJ, Ledbetter JA, Linsley PS, Tung KS. The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells. J Exp Med 1996; 183:801–810.PubMedGoogle Scholar
  120. 120.
    Carayanniotis G, Masters SR, Noelle RJ. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 1997;90:421–426.PubMedGoogle Scholar
  121. 121.
    Balasa B, Krahl T, Patstone G, et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997;159:4620–4627.PubMedGoogle Scholar
  122. 122.
    Howard LM, Miga AJ, Vanderlugt CL, et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J Clin Invest 1999;103:281–290.PubMedGoogle Scholar
  123. 123.
    Nakamura M, Tanaka Y, Satoh T, et al. Autoantibody to CD40 ligand in systemic lupus erythematosus: association with throm-bocytopenia but not thromboembolism. Rheumatology (Oxford) 2006;45:150–156.Google Scholar
  124. 124.
    Kelley SK, Geizleichter T, Xie D, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates. Br J Pharmacol 2006;148:1116–1123.PubMedGoogle Scholar
  125. 125.
    Tai YT, Li X, Tong X, et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005;65:5898–5906.PubMedGoogle Scholar
  126. 126.
    Tai YT, Li XF, Catley L, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005;65:11712–11720.PubMedGoogle Scholar
  127. 127.
    Shorts L, Weiss JM, Lee JK, et al. Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression. J Immunol 2006;176:6543–6552.PubMedGoogle Scholar

Copyright information

© Springer New York 2007

Authors and Affiliations

  1. 1.Clinical Immunology Laboratory, Center for Neurologic DiseasesBrigham and Women’s Hospital and Harvard Medical SchoolBoston
  2. 2.Center for Neurologic DiseasesHarvard Institutes of MedicineBoston

Personalised recommendations